GSK CEO Walmsley to step down, be succeeded by company’s commercial lead

Taking stock of the drug industry, from the lab to the medicine chest

September 29, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

STAT STAT+ | GSK CEO Walmsley to step down, be succeeded by company's commercial lead Walmsley has led GSK since 2017, focusing the company on innovative medicines. Miels has been running commercial operations. By Andrew Joseph STAT+ | AstraZeneca to list shares in New York while keeping London listing The company, which will also keep its U.K. headquarters, said the move would allow investors easier access to its regular shares. By Andrew Joseph STAT+ | Opinion: Lilly executives: How the FDA's new PreCheck program can unleash the future of U.S. medicine manufacturing The existing regulatory framework continues to delay turning investments into tangible progress for patients, Eli Lilly executives write By Jeffrey Francer and Victor Cruz Mario Tama/Getty Images STAT+ | Genmab to buy Merus in $8B deal The acquisition is centered on petosemtamab, a promising treatment for head and neck cancer that is in Phase 3 trials. By Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser